Background: In patients with triple-negative breast cancer (TNBC), the extent of tumor-infiltrating lymphocytes (TILs) in the residual disease after neoadjuvant chemotherapy (NACT) is associated with better prognosis. Our objective was to develop a gene signature from pretreatment samples to predict the extent of TILs after NACT and then to test its prognostic value on survival.
Introduction
Triple-negative breast cancer (TNBC) is characterized by the absence of expression of the estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2). Although the TNBC subtype is traditionally perceived as an aggressive disease, recent prospective trials suggest that not all patients immediately relapse after (neo)adjuvant chemotherapy. As illustration, in the BEATRICE trial, the 3-year invasive disease-free interval was 83% (95% CI 80.5-85.0) [1] . Hence, one of the major stakes in TNBC will be the identification of those patients who have excellent survival outcome when treated with conventional therapies as opposed to those who require new drugs. Several efforts are ongoing to identify prognostic parameters of survival in TNBC patients. Pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) is strongly correlated with more favorable outcome [2, 3] . The absence of pCR has been recently used as an inclusion criterion to enrich randomized trials with patients at high risk of relapse, therefore requiring new therapies. Tumor-infiltrating lymphocytes (TILs) are mononuclear immune cells that infiltrate tumor tissue and likely reflect an individual immunological response. In early breast cancer (BC), the presence of TILs and high immune infiltration defined by gene expression-related signatures are associated with more favorable outcome [4, 5] . We reported that the presence of >60% TILs in residual disease (RD) after NACT is associated with better prognosis in patients with TNBC [6] . In this study, 10% of patients had TILs >60% in their RD after NACT, and the 5-year OS rate was 91% in the high-TILs versus 55% in the low-TILs groups, respectively. This observation was recently confirmed in an independent study [7] . Therefore, the extent of post-NACT TILs is also associated with good outcome. Based on these data, we hypothesized that developing, from pre-NACT tumor samples, a molecular test able to predict the quantity of TILs within residual TNBC after NACT would be of prognostic value.
This study aimed to develop a genomic predictor of chemotherapy-mediated increase in TILs in patients with TNBC. As at baseline it is not known which patients will achieve a pCR, we also tested its prognostic value in an unselected population including both patients with pCR and RD. Such a tool could help identifying-at diagnosis-patients at high risk of recurrence, who might require novel immuno-stimulatory treatments within clinical trials.
Patients and methods

Patients
In the training set, patients were selected if they had an ER-/HER2-BC, treated with NACT (anthracycline-containing), RD after treatment, a gene expression array performed on pretreatment samples and hematoxylin and eosin (H&E)-stained tumor sections available to assess posttreatment TILs (see supplementary Figure S1 , available at Annals of Oncology online). Two patient series were included in the training set: 30 patients from Trial of Principle (TOP) study and 69 patients from MDACC neoadjuvant series [8, 9] (see supplementary Tables S1 and S5 , available at Annals of Oncology online). In the validation set, patients were selected if they had an ER-/HER2-BC treated with NACT (anthracycline-containing), RD after treatment, and a gene expression array performed on pretreament samples. Five cohorts of patients were included in the validation set: 24 patients from I-SPY-1, 16 patients from LBJ/ INEN/GEICAM, 20 patients from MAQCII/MDACC (those who were not included in the training set), 41 patients from TOP trial (those who were not included in the training set), and 14 patients from USO-02103 [9] [10] [11] [12] (see supplementary Tables S2 and S5 and Figure S2 , available at Annals of Oncology online). The TOP trial and the MDACC series were split between the training and validation set based on the availability of H&E slides. A larger validation set from the same five cohorts was considered for exploratory analyses and included patients with either pCR or RD. Detailed methods of TILs assessment and gene expression computation are provided in supplementary material (see supplementary  Figures S4 and Tables S3 and S4 , available at Annals of Oncology online).
Tumors were identified as ER-/HER2-based on ER assessment by IHC and HER2 assessment by IHC and fluorescent in situ hybridization, as originally reported [8] [9] [10] [11] [12] . When unavailable, ER and HER2 status were assigned according to ESR1 and ERBB2 gene expression [5] . In the validation set, 11 tumors were PgRþ by IHC. These tumors were included in our analysis, because considered triple-negative by gene expression in the original manuscripts [8] [9] [10] [11] [12] .
TILs were quantified on RD after NACT in H&E slides from surgical samples from MDACC neoadjuvant series and TOP trial (training set) [8, 9] , closely adhering to the criteria proposed by the TILs WG [13] , although they were developed for scoring pretreatment samples. Briefly, all mononuclear cells (i.e., lymphocytes and plasma cells) in the stromal compartment within the borders of the invasive tumor were evaluated and reported as a percentage (TILs score). TILs outside of the tumor border, around DCIS and normal breast tissue, as well as in areas of necrosis, if any, were not included in the scoring. TILs have been evaluated for the stromal compartment only (¼percentage of stromal TILs), as per the TILs WG recommendations [13] . TILs were assessed as a continuous measure (score). For each surgical specimen, all the slides containing invasive RD have been evaluated. The reproducibility of this method has been described [5] . H&E slides from TOP samples have been sent to IEO, where they have been independently read for TIL infiltration by two investigators (CC and GP). MDACC H&E slides have been read on-site by two investigators (CC and BS). In case of disagreement between investigators, the score was assigned by consensus.
Methods
Spearman correlation was used to quantify the correlation between preand posttreatment TILs, and a Wilcoxon signed-rank test was performed to assess whether there was an increase in the average posttreatment TILs as compared with baseline samples. To assess the prognostic value of post-NACT TILs on survival, we used a Cox model adjusted for age (continuous), cT (T0-1-2 versus T3-4), cN (N0 versus Nþ) and grade (1-2 versus 3), and stratified by patient series (TOP versus MDACC).
The first step in constructing the genomic signature was gene selection. As the most appropriate cut-off is controversial, we fitted a general linear model of the continuous level of TILs after Box-Cox transformation as a function of gene expression, while controlling for the effect of potential confounders, i.e. series (TOP versus MDACC), age (continuous), cT (T0-1-2 versus T3-4), cN (N0 versus Nþ), and grade (1-2 versus 3). To identify a parsimonious set of genes, we used the lasso penalization for variable selection with the optimal value of the tuning parameter obtained from a 10-fold cross validation process [14, 15] (see supplemen tary Figure S5 , available at Annals of Oncology online). The clinicopathologic covariates included in the model were not penalized.
We estimated pairwise correlation values between the genes included in the four-gene signature using the Spearman correlation; 95% confidence intervals (CI) were obtained using 1000 bootstrap repetitions.
The four-gene signature was defined as the linear combination of the gene expressions weighted by the regression coefficients in the general linear model; to facilitate interpretation of the values of the four-gene signature thus obtained, the signature was scaled within the training set, so that the 2.5% and 97.5% quantiles equaled 0 and þ1, respectively. To assess the accuracy of the model to predict the observed value of TILs, we computed the root mean squared prediction error (RMSE) using 1000 repetitions of a 10-fold cross validation.
We computed the four-gene signature on the validation set using the same probes and the same coefficients as for the training set. We scaled the four-gene signature in the validation set using the same values as used in the training set. Distant relapse-free survival (DRFS) was defined as time from initial diagnosis to distant relapse or death. Patients who did not experience the event were censored at the date of the last follow-up.
The median follow-up was computed using inverse Kaplan-Meier method applied on DRFS [16] . To assess the prognostic value of the signature on DRFS in the training set and then in validation set, we computed hazard ratios (HRs) and 95% CIs using a Cox model stratified on series and adjusted on clinicopathologic variables. As defining if a patient achieved pCR or not requires a 6-month observation period, for patients in the validation set with RD, landmarking was used with a landmark time at 6 months [17] . This technique was not used for the entire validation set. We built two risk groups (four-gene signature low versus fourgene signature high) using the median value of the four-gene signature in the training set as a cut-off. The cut-off was then frozen for the entire study and used to build risk groups in the validation set.
We used Uno's concordance index (C-index) to quantify the capacity of the prediction models to discriminate subjects with different event times [18] . We considered two truncation times: a horizon at 3 years and 5 years. The resulting Cs tell how well the given prediction models work in predicting events that occur in the time window from 0 to 3 years and 0 to 5 years, respectively. 95% CIs were obtained using 1000 bootstrap repetitions. We used the likelihood ratio test to assess the added value of the four-gene signature to the clinical model including the clinicopathologic covariates determined at diagnosis in the training set and then in the validation set.
We explored the association between the four-gene signature and the probability to achieve pCR in the entire validation set, we computed odds ratios (ORs) and 95% CI using a conditional logistic model stratified on series and adjusted on clinicopathologic variables.
For all statistical models, we used restricted cubic splines with two degrees of freedom to investigate nonlinear associations.
Secondary analysis consists in modeling TILs from the training set using univariate selection (one gene at a time) adjusted on clinicopathological variables with correction for multiple comparisons. For detailed statistical methods, see supplementary Table S19 , available at Annals of Oncology online [19] .
Results
Study population
Overall, 99 patients with ER-/HER2-BC were selected to generate the signature. Although five of these patients did not have survival data, they were included because H&E sections to determine posttreatment TILs and baseline gene expression data were available. Hence, they could be entered in our primary model to determine a gene expression score associated with posttreatment TILs. Of note, 115 patients with ER-/HER2-BC and RD were selected to validate the prognostic value of the signature on DRFS. The entire validation set included 185 patients whether they achieved pCR. Patients' characteristics in the training set and validation set are given in Table 1 . Flowcharts for the training set and validation set are described in supplementary material (see supplementary Figures S1 and S2, available at Annals of Oncology online).
Tumor-infiltrating lymphocytes
The median value of stromal-TILs after NACT was 15% (range 0%-95%) in the training set. Detailed summary statistics of TILs after NACT and description of the Box cox transformation are provided in supplementary material (see supplementary Table  S4 , available at Annals of Oncology online). Pre-and post-NACT TILs were both available for 29 patients from the training set.
There was no statistically significant correlation between pre-and posttreatment TILs (Spearman correlation coefficient ¼ 0. Figure S3 , available at Annals of Oncology online). Postchemotherapy TILs were associated with improved DRFS in a multivariate analysis including age, cT, cN and grade, and stratified by series (HR for a 10% increase in TILs: 0.83, 95% CI: 0.68-0.99, P ¼ 0.043). A similar trend was observed for OS (HR for a 10% increase in TILs: 0.83, 95% CI: 0.69-1.01,
Development of a four-gene signature on pretreatment samples to predict post-NACT TILs
The LASSO penalized regression model of the level of TILs after NACT led to a parsimonious set of four probes of four different genes (HLF, CXCL13, SULTE1, and GBP1) that are provided with their corresponding coefficients in Table 2 . Detailed information about model selection and pairwise correlation values among the four probes is provided in supplementary material (see supplementary Tables S6, S7 , S16, S17, S20-S23 and Figures  S6 and S8 , available at Annals of Oncology online). The four-gene signature was strongly associated with TILs; the corrected RMSE using cross-validation was 2.21 (95% CI; 2.15-2.28; for more details see supplementary Tables S9 and S10 and Figure S7 , available at Annals of Oncology online).
Prognostic value of the four-gene signature in the training set
The prognostic value of the four-gene signature was assessed in 94 patients from the training set, for whom survival data were available. All patients had RD after NACT. Median (Q 1 À Q 3 ) follow-up was 7.6 years (3.7-8.8). In a multivariate analysis (Table 3) , the four-gene signature was significantly associated with better DRFS (HR for a one-unit increase in the value of the 4-gene signature: 0.28, 95% CI: 0.13-0.63, P ¼ 0.002). KaplanMeier DRFS curves of the risk groups (low four-gene signature versus high four-gene signature) constructed using the median value of the four-gene signature (median ¼ 0.51) are shown in Figure 1A . There was no evidence of a nonlinear association between the four-gene signature and DRFS. The four-gene signature added significant prognostic information to the clinicopathological characteristics at diagnosis, as shown by the likelihood ratio test (P ¼ 0.004). The discrimination was also improved; at 5 years, the C-index increased from 0.617 to 0.673 (Table 4) . Similar results were obtained for OS (HR for a one-unit increase in the value of the four-gene signature: 0.35, 95% CI: 0.16-0.75, P ¼ 0.007; likelihood ratio test, P ¼ 0.012; the C-index increased from 0.631 to 0.668).
Prognostic value of the four-gene signature in the validation set
In the validation set, 68 (37%) patients achieved pCR and 115 (63%) had RD (two missing information). We first evaluated the prognostic value of the four-gene signature in patients with RD (n ¼ 115), as in the training set (see supplementary Tables S7-S9 , available at Annals of Oncology online). In a multivariate analysis (Table 3) , the four-gene signature was significantly associated with DRFS (HR for a one-unit increase: 0.17, 95% CI: 0.06-0.43, P ¼ <0.001). Kaplan-Meier DRFS curves of the risk groups constructed using the same cut-off (0.51) as in the training set are shown in Figure 1B . No significant nonlinear association between four-gene signature and DRFS was brought out. When adding the four-gene signature to the clinicopathologic characteristics, GSE16446  GSE25066  GSE25066  GSE25066  GSE20194  GSE20194  GSE20271  GSE16446  GSE16446  GSE23988  GSE23988  References Hatzis et al. [7] Hatzis et al. [7] Hatzis et al. [7] Desmedt et al. [8] Desmedt et al. [8] Desmedt et al. [8] Shi et al. [10] Shi et al. [10] Iwamoto et al. [11] Iwamoto et al. [11] Data are mean (SD), median (Q1-Q3), min-max, or n (%). Patients of the training set were from MDACC neoadjuvant series and TOP study [7, 8] . SD, standard deviation; Q1, 25th percentile; Q3, 75th percentile; Min, Minimum; Max, Maximum; cT, clinical tumor size; cN, clinical nodal status; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TILs, tumor-infiltrating lymphocytes; GEO, gene expression omnibus; N/A, not available.
there was an added prognostic value, as shown by the likelihood ratio test (P ¼ 0.002). Discrimination ability was also improved; at 5 years, the C-index increased from 0.712 to 0.749 in the validation set for patients with RD. As part of the exploratory analyses, we then assessed the prognostic value in the overall population irrespective of the pathological response to NACT (pCR versus RD). In a multivariate analysis (n ¼ 185), the four-gene signature was significantly associated with improved DRFS (HR: 0.29, 95% CI: 0.13-0.67, P ¼ 0.004, Table 3 ), after controlling for clinicopathologic covariates and response to NACT. Kaplan-Meier DRFS curves of the risk groups constructed using the same cut-off (0.51) as in the training set are shown in Figure 1C . No significant nonlinear association between the four-gene signature and DRFS was brought out. When adding the four-gene signature to the clinicopathologic characteristics, there was an added prognostic value, as shown by the likelihood ratio test (P ¼ 0.008). Discrimination ability was also improved; at 5 years, the C-index increased from 0.686 to 0.700 in the validation set for all patients (pCR and RD).
Results of the conditional logistic model showed no statistically significant association between the four-gene signature and the probability to achieve pCR in the validation set (OR for a oneunit increase in the four-gene signature: 0.96, 95% CI: 0.30-3.08, P ¼ 0.947). No significant nonlinear association between the four-gene signature and the probability to achieve pCR was brought out (see supplementary Table S18 , available at Annals of Oncology online).
Discussion
There is a large body of evidence supporting the immunogenic role of chemotherapy and the association between immune system activation and good outcome [20] . However, the molecular predictors of this effect are still to be found. Preliminary data have suggested that autophagic markers and genetic polymorphisms on Toll-like receptor 4 (TLR4), P2X purinoceptor 7 (P2RX7), fusion regulatory protein-1 (FRP1) may define a subset in which chemotherapy could generate an adaptive immune response [21] . In this study, we report the development of a four-gene signature that predicts high levels of TILs after anthracycline-containing chemotherapy. Guanylate-binding The four-gene signature is the linear combination of the gene expressions weighted by the regression coefficients; to facilitate the interpretation of the values of the four-gene signature thus obtained, the signature was scaled within the training set, so that the 2.5% and 97.5% quantiles equaled 0 and þ1. A positive coefficient indicates that an increasing gene expression is associated with an increased quantity of TILs. A negative coefficient indicates that an increasing gene expression is associated with a decreased quantity of TILs. protein 1 (GBP1) and chemokine (C-X-C motif) ligand 13 (CXCL13) are two proteins involved in antitumor immune response. GBP1 is an interferon-regulated protein involved in cancer cell apoptosis following inflammatory response. Interferon response has previously been proven to be a major component of chemotherapy-induced adaptive immune response. CXCL13 is a chemokine involved in B-cell attraction. CXCL13 expression is regulated through Th17 response, a mechanism of immunogenic cell death [22] . The link between immune system and Sulfotransferase Family 1E Member 1 (SULT1E1)/hepatic leukemia factor (HLF) is less obvious and will deserve further preclinical explorations. SULT1E1 is a gene involved in the transformation from E1 to E2, and its suppression could create a more immunogenic microenvironment [23] . HLF is a transcription factor that could be involved in treatment induced immunogenic cell death [24] . Pretreatment TILs have been associated with very good outcome in patients with TNBC.
The four-gene signature developed in the training set may predict the extent of posttreatment TILs and prognosis. In the validation set, only the prognostic value of the four-gene signature was confirmed. The predictive value of the signature on posttreatment TILs has not been independently validated yet.
To what extent the four-gene signature adds information to TILs is a matter of discussion. Unfortunately, we could not assess pretreatment TILs in the vast majority of patients included in this study. Nevertheless, there are three arguments suggesting that the four-gene signature could be complementary and/or add information to pretreatment TILs. First, the integrated prognostic model of clinicopathological factors plus the four-gene signature will allow to detect more patients with low risk of relapse as compared with the use of pretreatment TILs and its conventional cut-off (>50% TILs), which only identifies 10% of TNBC as TILs-positive [6] . Second, the vast majority of patients with high TILs after NACT do not present TILs in baseline samples. As illustration, in the study reported by Dieci et al., 13 of 18 patients Figure 1 . Kaplan-Meier survival curves for (A) distant relapse-free survival in the training set, (B)distant relapse-free survival in the patients from the validation set who did not achieve pCR (primary analysis), (C) distant relapse-free survival in the entire validation (exploratory analysis) set for patients who achieved pCR or not, and (D) overall survival in the training set. Risk groups for the training set and the validation set as well are constructed using the training set median value of the four-gene signature (median ¼ 0 Á 51). HR, Hazard ratio; CI, confidence interval; P, P-value.
with post-NACT TILs had <60% TILs in baseline samples [6] . In the present study, there was no strong correlation between preand posttreatment TILs (P ¼ 0.384) in the limited set of samples for which both TILs values were obtained, and posttreatment TILs were increased as compared with baseline samples (Wilcoxon signed-rank test P-value ¼ 0.002). Third, we believe that pretreatment TILs and the four-gene signature reflect two separate mechanisms of antitumor activity. Pretreatment TILs have been associated with pCR in several independent studies, whereas the four-gene signature has been developed specifically in patients with RD [25, 26] . Altogether, these considerations suggest that pretreatment TILs and our four-gene signature will be complementary in assessing outcome in patients with TNBC.
Furthermore, we compared the added value of the four-gene signature with two immune-related signatures (immune 1 and immune 2, one at a time) in both training and validation sets [5] (see supplementary Tables S9-S12, available at Annals of Oncology online). The four-gene signature was not strongly correlated to any of these two signatures in any dataset. Our signature adds statistically significant independent prognostic information to a model including clinicopathological variables and either of these two immune signatures already known to predict outcome in TNBC [5] (see supplementary Tables S13-S15, available at Annals of Oncology online). Hence, this significantly improves the strength of our finding, partially circumventing the lack of information about pretreatment TILs.
There are several ways to further position this signature in daily practice. First, the four-gene signature could be used at diagnosis in an integrated clinicopathological model to predict patients at high risk of relapse when treated with neoadjuvant anthracyclinecontaining chemotherapy, who may therefore require additional therapies. In the validation set, the signature was associated with an increased likelihood of metastatic relapse (HR ¼ 1.94, 95% CI: 1.05-3.60). Second, because the signature is not associated with pCR, it lends itself naturally to a model including a molecular predictor of pCR. Increased pCR rate has not been shown to correlate with prolonged event-free survival. Our findings contribute to explain this lack of correlation. Indeed, we have shown thateven in patients with RD-a treatment-induced TILs' upregulation may correlate with clinical benefit that cannot be captured by the simple pCR rate. This may be another way to look at treatment efficacy, even in the absence of significant change in pCR rate. As mentioned earlier on, a score combining pretreatment TILs and the four-gene signature could be a good candidate to optimally predict relapse by combining a predictor of pCR and a predictor of high TILs following NACT.
If we can define a subset of patients who will not show chemoimmunization, then the major issue is how to improve their outcome. One possible strategy could consist in targeting the inhibitors of chemo-immunization, like MEK [7] . HLF and SULT1E1, two genes included in our signature, are targetable and further preclinical studies will determine whether their modulation could enhance the chemotherapy-induced immune response.
In conclusion, the four-gene signature identifies, based on baseline samples, those patients who will present high TILs after NACT and is associated with good outcome. Further steps will consist of integrating the signature with clinical parameters and pretreatment TILs, as well as the evaluation of targetable proteins (HLF/SULT1E1) in preclinical studies. Uno's concordance indices were computed to quantify the capacity of the prediction models in discriminating among subjects with different event times. Two truncation times were considered: 3 and 5 years. The concordance indices indicate how well the given prediction models work in predicting events that occur in the time range from 0 to 3 years and 0 to 5 years, respectively. The likelihood ratio statistics was used in Cox regression models stratified on center to estimate the added value of the four-gene signature to the clinical models. 95% confidence intervals were obtained using 1000 bootstrap repetitions. CM, clinical model; C-index, concordance index; DRFS, distant relapse-free survival; OS, overall survival.
